§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇪🇬Egypt	🇬🇧United Kingdom
Authority & dossier
Regulatory authority	EDA	MHRA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	FDA, EMA, Health Canada, Swissmedic +4
Lead pathway (timeline & fees) — New Drug Registration — Standard Review · International Recognition Procedure (IRP)
Pathway name	New Drug Registration — Standard Review	International Recognition Procedure (IRP)
Approval timeline	365–730 days	60–110 days
Application fee	EGP 100,000	GBP 35,305
Annual renewal	EGP 0	GBP 0
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Not required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	MAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.	Qualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.
Accelerated pathways
Designations available	3 designations	4 designations
Examples	Reliance / Verification — Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme	Early Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1
Post-approval lifecycle
Variations framework	Variations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor — prior approval), Type II (major — prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.	Variations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.
Renewal cycle	Drug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.	Initial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.
Pharmacovigilance	The Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	MHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–120 days	30–60 days
GCP standard	ICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration	ICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	No
HTA required	No	Yes
HTA body	No formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.	NICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

EgyptEDA
United KingdomMHRA

English submissions

EgyptYes
United KingdomYes

CTD accepted

EgyptYes
United KingdomYes

eCTD accepted

EgyptYes
United KingdomYes

Reliance pathway

EgyptAvailable
United KingdomAvailable

Reference agencies

EgyptFDA (US), EMA, MHRA (UK), Health Canada +4
United KingdomFDA, EMA, Health Canada, Swissmedic +4

Lead pathway (timeline & fees) — New Drug Registration — Standard Review · International Recognition Procedure (IRP)

Pathway name

EgyptNew Drug Registration — Standard Review
United KingdomInternational Recognition Procedure (IRP)

Approval timeline

Egypt365–730 days
United Kingdom60–110 days

Application fee

EgyptEGP 100,000
United KingdomGBP 35,305

Annual renewal

EgyptEGP 0
United KingdomGBP 0

Local representative

EgyptRequired
United KingdomNot required

Local manufacturing

EgyptNot required
United KingdomNot required

GMP inspection

EgyptRequired
United KingdomNot required

MAH & local presence

Local entity required

EgyptYes
United KingdomYes

Local responsible person

EgyptYes
United KingdomYes

RP role

EgyptMAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.
United KingdomQualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.

Accelerated pathways

Designations available

Egypt3 designations
United Kingdom4 designations

Examples

EgyptReliance / Verification — Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme
United KingdomEarly Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1

Post-approval lifecycle

Variations framework

EgyptVariations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor — prior approval), Type II (major — prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.
United KingdomVariations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.

Renewal cycle

EgyptDrug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.
United KingdomInitial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.

Pharmacovigilance

EgyptThe Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
United KingdomMHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.

Unlicensed access

Named Patient Supply

EgyptAvailable
United KingdomAvailable

Compassionate Use

EgyptAvailable
United KingdomAvailable

Emergency Import

EgyptAvailable
United KingdomAvailable

Parallel Import

EgyptNot permitted
United KingdomPermitted

Clinical trials

CTA approval

EgyptRequired
United KingdomRequired

Ethics approval

EgyptYes
United KingdomYes

CTA timeline

Egypt60–120 days
United Kingdom30–60 days

GCP standard

EgyptICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration
United KingdomICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)

Pricing & reimbursement

Price regulation

EgyptRegulated
United KingdomRegulated

Reference pricing

EgyptYes
United KingdomNo

HTA required

EgyptNo
United KingdomYes

HTA body

EgyptNo formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.
United KingdomNICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)